Mesenchymal Stem Cells Market Size - By Type (Autologous, Allogeneic), Source (Adipose Tissue, Bone Marrow), Indication (Bone & Cartilage Repair, Cardiovascular Diseases), Application & Global Forecast, 2023 - 2032

Mesenchymal Stem Cells Market Size - By Type (Autologous, Allogeneic), Source (Adipose Tissue, Bone Marrow), Indication (Bone & Cartilage Repair, Cardiovascular Diseases), Application & Global Forecast, 2023 - 2032

Mesenchymal Stem Cells Market Size

Mesenchymal Stem Cells Market size accounted for USD 3 billion in 2022 and is estimated to grow at 12.8% to reach USD 10.3 billion by 2032 due to the rising prevalence of chronic diseases such as cancer, autoimmune disease, diabetes coupled with increasing implication in the field of immune therapy, drug discovery and regenerative medicine.
 

For instance, in 2019, according to the World Health Organization (WHO), 18 million people globally were suffering from rheumatoid arthritis. Thus, rising prevalence of autoimmune disease is significantly propelling the demand for mesenchymal stem cells to develop effective therapies. Furthermore, increasing R&D activities by biopharmaceutical companies and growing application of mesenchymal stem cells in toxicology and safety testing.
 

Mesenchymal stem cells (MSCs) are a type of multipotent stem cells that can differentiate into various cell types like bone, cartilage, and fat within the body's mesodermal lineage. These cells are found in various tissues of the body, such as bone marrow, adipose tissue, umbilical cord among others that possess self-renewal capabilities, enabling them to multiply and generate more MSCs. These cells offer distinctive feature and their ability to modulate the immune system, make them appealing for therapeutic applications in areas such as tissue repair, regenerative medicine, and immune modulation.
 

COVID-19 Impact

The emergence of the COVID-19 pandemic had significantly positive impact on the field of mesenchymal stem cells (MSCs) by directing attention toward their potential therapeutic applications. MSCs have shown promising results in managing COVID-19-related complications, particularly in addressing the severe inflammatory responses and lung damage associated with the virus. Early clinical trials and studies suggest that MSCs' immunomodulatory properties helps to mitigate the excessive immune response observed in severe cases of COVID-19, potentially reducing the severity of symptoms and improving patient outcomes. For instance, according to the ClinicalTrial.gov report, mesenchymal stem cells were investigated to determine the efficacy, effective and safe approach for the treatment of COVID-19 infection. This has led to increased research and investment in utilizing MSCs as a potential adjunct therapy for COVID-19 patients.
 

Mesenchymal Stem Cells Market Trends

Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular ailments, and degenerative disorders have created significant demand for transformative therapies. Mesenchymal stem cells offers regenerative properties and immunomodulatory capabilities that position them as a promising candidates for treating chronic conditions by promoting tissue repair and modulating inflammatory responses. For instance, in 2020, according to the American Cancer Society, over 1.8 million new cancer cases were reported, and 606,520 people died of cancer in U.S. Similarly, in 2022, according to Parkinson’s Foundation, over 10 million people are suffering from Parkinson’s disease globally.
 

Mesenchymal Stem Cells Restraint

Lack of standardized protocols and comprehensive regulations acts as a notable barrier to the widespread adoption of mesenchymal stem cells that may potentially hamper the mesenchymal stem cells market. The absence of standardized procedures for MSC isolation, expansion, and administration can lead to variability in outcomes, making it difficult to ensure the safety and efficacy of treatments. Regulatory uncertainties and variations in approval processes across different regions further complicate the landscape, impeding the smooth progression of MSC therapies from research to clinical practice. Hence, lack of synchronisation not only impacts patient outcomes but also hampers the business environment, as biopharmaceutical companies face obstacles in navigating complex regulatory frameworks and ensuring the reproducibility of therapies.
 

Mesenchymal Stem Cells Market Analysis

By products & services, the mesenchymal stem cells market is classified into products and services. The products segment accounted for 76.8% of the market share in 2022. Mesenchymal stem cell products are further sub-segmented into kits, media, and reagents, cells & cell lines and other products. Kits and reagents are designed for mesenchymal stem cells research streamline experimental processes, ensuring accuracy and reproducibility. They provide optimized culture media & necessary components, reducing variability and expediting research timelines. Also, cells and cell lines offer consistent and reproducible material for studying stem cell behaviour, differentiation, and therapeutic potential.
 

By type, the mesenchymal stem cells market is classified into autologous and allogeneic. The allogeneic segment accounted for USD 1.8 billion market revenue in 2022. Allogeneic mesenchymal stem cells are sourced from compatible donors, providing a readily available supply for therapeutic applications without the necessity of obtaining cells from the patient's own tissues. This approach circumvents the time-consuming process of isolating autologous cells. Also, the scalability of allogeneic MSC production contributes to cost-effectiveness and broader accessibility. They can be thoroughly characterized and quality-controlled before use, ensuring consistent and reliable cell populations.
 

Based on source, the mesenchymal stem cells market is segmented into adipose tissue, bone marrow, cord blood, fetal liver, fallopian tube, lung, peripheral blood and other sources. The bone marrow segment is expected to register USD 2.6 billion by 2032. Increasing segmental progression is owing to relatively high concentration of mesenchymal stem cells in bone marrow as compared to other tissues. Also, mesenchymal stem cells derived from bone marrow exhibit robust proliferation capabilities that can be expanded in culture over multiple passages without losing their stem cell characteristics. Furthermore, robust regenerative potential and ability to differentiate into various cell types, mesenchymal stem cells derived from bone marrow hold promising potential in accelerating tissue repair, addressing degenerative disorders, and modulating immune responses.
 

By indication, the mesenchymal stem cells market is segmented into bone & cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, graft versus host disease (GvHD) and other indications. The cardiovascular diseases segment is expected to grow at 11.8% by 2032. Mesenchymal stem cells offer significant regenerative potential in repairing damaged heart tissue, promoting angiogenesis, and enhancing cardiac function. These versatile stem cells offer distinct advantages in treating several conditions such as heart failure, myocardial infarction, vascular disorders among others. Also, their immunomodulatory properties further contribute to minimizing inflammation and immune responses that exacerbate cardiovascular damage.
 

The application in mesenchymal stem cells market is categorized into disease modeling, drug development & discovery, stem cell banking, tissue engineering, toxicology studies and other applications. Disease modeling segment accounted for USD 1.1 billion market revenue in 2022. Disease modeling involves replicating pathological conditions in a controlled environment to study disease mechanisms and potential treatments. Mesenchymal stem cells are well-suited for this purpose due to their versatility and immunomodulatory properties. They can be induced to differentiate into various cell types relevant to specific diseases, providing researchers with a platform to study disease progression and cellular interactions. Additionally, MSCs' immunomodulatory capabilities contribute to mimicking inflammatory responses seen in certain diseases. This enables researchers to observe cellular behaviour and test therapeutic interventions with greater accuracy.
 

North America mesenchymal stem cells market accounted for 42.4% market share in 2022. Increasing regional growth is owing to robust research infrastructure coupled with a strong emphasis on medical innovation, leading to a thriving environment for MSC-related advancements. Further, growing demand for effective disease diagnosis & therapies and favorable government regulations further support the expansion of mesenchymal stem cells.
 

Mesenchymal Stem Cells Market Share

Major market players operating in the mesenchymal stem cells market

• Thermo Fisher Scientific, Inc.
• Cell Applications, Inc.
• Cyagen Biosciences
• Lonza
• PromoCell GmbH 
   

Mesenchymal Stem Cells Industry News

• In May 2023, Pluristyx partnered with Stemmatters to accelerate the development of induced pluripotent stem cell (iPSC)-derived advanced therapies. This strategy will help the company to advance proprietary iMSC technology into the clinic and accelerate the development of innovative iPSC-based therapies.
   
• In February 2019, Pluristem Therapeutics collaborated with NASA's Ames Research Center. This collaboration aimed to enhances and evaluate the potential of Pluristem's PLX cell therapies in preventing and treating medical conditions caused during space missions. This strategic collaboration helped the company to explore the possibility that PLX placenta-based cell therapy products can address persistent negative effects of space travel on the human body.
   

The mesenchymal stem cells market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Products & Services

• Products
  • Kits, media, & reagents
  • Cells & cell lines
  • Other products    
• Services

By Type

• Autologous
• Allogeneic

By Source

• Adipose tissue
• Bone marrow
• Cord blood
• Fetal liver
• Fallopian tube
• Lung
• Peripheral blood
• Other sources

Indication

• Bone & cartilage repair
• Cardiovascular diseases
• Inflammatory and immunological diseases
• Liver diseases
• Cancer
• Graft versus host disease (GvHD)
• Other indications

Application

• Disease modeling
• Drug development & discovery
• Stem cell banking
• Tissue engineering
• Toxicology studies
• Other applications

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA